Bank of New York Mellon
IMNP

Bank of New York Mellon’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Bank of New York Mellon’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-14,670
Closed -$5K – 4374
2018
Q1 		$5K Buy
+14,670
New +$6.98K ﹤0.01% 4303
2017
Q2 		– Sell
-4,846
Closed -$14K – 4382
2017
Q1 		$14K Buy
+4,846
New +$17.5K ﹤0.01% 4244

Other funds holding IMNP

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon's IMNP Position: Q2 2018 in Review

Bank of New York Mellon sold out of Immune Pharmaceuticals Inc. (IMNP) in Q2 2018, closing a stake of 14,670 shares — an estimated $5K sold.

Bank of New York Mellon first reported a position in IMNP in Q1 2017 and held it in 2 quarters. The position peaked at $14K in Q1 2017. 13 funds tracked by Wall St. Rank hold IMNP as of Q2 2018.

  • Bank of New York Mellon reported no remaining Immune Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • Bank of New York Mellon sold 14,670 Immune Pharmaceuticals Inc. shares in Q2 2018, an estimated $5K.
  • Bank of New York Mellon first reported a position in Immune Pharmaceuticals Inc. in Q1 2017 and held it in 2 quarters.
  • Bank of New York Mellon's Immune Pharmaceuticals Inc. position peaked at $14K in Q1 2017.
  • 13 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q2 2018.

Based on Bank of New York Mellon's 13F filing for Q2 2018, filed 6 Aug 2018.